/PRNewswire/ Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong.
Inhibrx, Inc. (NASDAQ:INBX – Get Rating) fell 7.4% on Monday . The company traded as low as $15.83 and last traded at $15.88. 54,717 shares were traded during mid-day trading, a decline of 86% from the average session volume of 400,795 shares. The stock had previously closed at $17.15. Wall Street Analysts Forecast Growth A […]